Emergent BioSolutions (EBS) Operating Margin Growth (5y) (2016 - 2026)

Emergent BioSolutions (EBS) Operating Margin Growth (5y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Emergent BioSolutions 389.77 Mn 228.27 Mn 84.10 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1,773.00
Dec 31, 2025 -6,303.00
Sep 30, 2025 1,719.00
Jun 30, 2025 -3,079.00
Mar 31, 2025 2,848.00
Dec 31, 2024 -2,647.00
Sep 30, 2024 -72.00
Jun 30, 2024 -40,412.00
Mar 31, 2024 2,762.00
Dec 31, 2023 -1,997.00
Sep 30, 2023 -10,176.00
Jun 30, 2023 -11,702.00
Mar 31, 2023 -8,177.00
Dec 31, 2022 -4,414.00
Sep 30, 2022 -5,086.00
Jun 30, 2022 -3,991.00
Mar 31, 2022 -1,049.00
Dec 31, 2021 557.00
Sep 30, 2021 -4,044.00
Jun 30, 2021 412.00